Fortimedix Surgical Announces Line Extension Of Surgical Solutions Portfolio With symphonX Instruments Short
Published: Aug 07, 2017
NUTH, The Netherlands and SAN DIEGO, Aug. 07, 2017 (GLOBE NEWSWIRE) -- Fortimedix Surgical today announced the official U.S. launch of its product line extension with symphonX™ Instruments short. The new product line offers shorter instruments that broaden surgical applicability of the symphonX™ Surgical Platform, further increasing the ease of use for surgeons during specific surgical procedures.
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/ba3500cd-9477-42ff-a33c-8292466f85b3
symphonX™ is the world’s lowest profile single-port surgery solution for use in minimally invasive abdominal laparoscopic surgery. The symphonX™ Instruments portfolio includes various products for grasping, mobilizing, dissecting, retracting, cutting, cauterizing, ligating, and suction/irrigation of tissues and vessels. With this line extension, these different types of instruments are available in a short version. Choosing the appropriate symphonX™ Instruments for a specific surgical procedure, patient anatomy and/or operative site is at the physician’s discretion.
“This product line extension was developed in response to surgeon feedback,” said David Castiglioni, Vice President Sales of Fortimedix Surgical. “We have used these shorter instruments during cholecystectomy, inguinal hernia repair and several gynecologic procedures including tubal sterilization and ovarian cyst treatment with positive results, confirming the versatility of the platform across surgical specialties. The launch of symphonX™ Instruments short signifies a substantial milestone as we continue to execute on our strategy to establish broad based market adoption of symphonX™ and elevate the standard of care in laparoscopy.”
For additional information or product specifications on symphonX™ Instruments short visit www.fortimedixsurgical.com.
symphonX™ is the world’s first single-port surgery solution compatible with a standard 15mm laparoscopic trocar. Emulating conventional, multi-port laparoscopy makes symphonX™ easy to use and enables surgeons to perform procedural steps ergonomically, allowing for a comfortable and secure single-port approach. symphonX™ is poised to deliver on the promise of single-port surgery, including fewer port-site complications, less post-operative pain, faster recovery and exceptional cosmesis, elevating the standard of care in laparoscopy.
About Fortimedix Surgical
Fortimedix Surgical is a fast growing medical device company, aiming to challenge the status quo in minimally invasive surgery by creating novel devices that capture the claimed benefits of single-port surgery. The company is headquartered in Nuth, The Netherlands, and has a U.S. subsidiary in San Diego, CA. With a strong history as a global market leader in contract stent manufacturing, Fortimedix has been a trusted partner in the medical device industry for almost two decades. Fortimedix Surgical is committed to driving the evolution of minimally invasive surgery through smart innovation across surgical specialties to improve the quality of life of patients throughout the world.
For more information, please visit www.fortimedixsurgical.com
Certain statements herein include “forward-looking” statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements generally can be identified by the use of forward-looking terminology, such as “may,” “will,” “expect,” “intend,” “estimate,” “anticipate,” “believe,” “project” or “continue” or the negative thereof or other similar words. All forward-looking statements involve risks and uncertainties, including, but not limited to, the protection of intellectual property, changes to governmental regulation of medical devices, the introduction of new products into the marketplace by competitors, changes to the competitive environment, the acceptance of new products in the marketplace, conditions of the surgical industry and economic and political conditions globally. Actual results may differ materially from those contemplated or implied by the forward-looking statements. The forward-looking statements speak only as of the date of this release and Fortimedix Surgical assumes no duty to update them to reflect new, changing or unanticipated events or circumstances.
For media inquiries, please contact: Fortimedix Surgical B.V., Monique Biermans, firstname.lastname@example.org, +31 (0)6 24 676 376 Digital press release available at: www.fortimedixsurgical.com/news-events Lazar Partners, Chantal Beaudry, email@example.com, or Amy Feldman, firstname.lastname@example.org, +1 (212) 867-1762